NICE (the National Institute for Health and Care Excellence) have released for consultation, a new set of draft guidelines for healthcare …
NICE Consultation on Guidelines for Suspected Neurological ConditionsRead More
August 14, 2017 by abzali123
NICE (the National Institute for Health and Care Excellence) have released for consultation, a new set of draft guidelines for healthcare …
NICE Consultation on Guidelines for Suspected Neurological ConditionsRead More
August 14, 2017 by abzali123
A number of pharmaceutical and biotech companies working in the field of Duchenne muscular dystrophy, have recently reported their 2nd quarter …
August 14, 2017 by abzali123
In the seventh interview in the “Portrait of Duchenne” series, our Canadian partners, La Force talked with Ravi Mehta at the Action …
August 14, 2017 by abzali123
Researchers at Cardiff University, in collaboration with biotechnology company PerkinElmer, have created a more reliable test to screen newborn babies …
Test with the Potential to More Reliably Screen for Duchenne in Newborns is DevelopedRead More
August 9, 2017 by abzali123
Mitobridge, Inc., a pioneer in the discovery and development of products that improve mitochondrial function, today announces a key milestone with the …
Mitobridge’s Potential Treatment for Duchenne Advances into Clinical DevelopmentRead More
August 9, 2017 by abzali123
The med-tech biopharmaceutical company, SOM Biotech, has granted a licence agreement with Corino Therapeutics Inc. for its first product SOMO266 for …
Worldwide licence for new drug SOMO266 as SOM Biotech expands to the United StatesRead More
August 1, 2017 by abzali123
A new study has started at Queen’s University Belfast. They are looking for young people aged 16-24 with a life-limiting condition and who …
July 25, 2017 by abzali123
Summit are looking for feedback from caregivers and patients themselves in their commitment to working alongside patients, their families …
Give your feedback to Summit in their Utrophin modulator patient/family surveyRead More
July 25, 2017 by abzali123
The likelihood of having a comorbid mental health condition is higher for neurology patients than for the long-term conditions patient population …
July 25, 2017 by abzali123
In the fifth interview of the series “Portrait of Duchenne”, our Canadian partners La Fondation La Force talked with Joanne …
July 25, 2017 by abzali123
In this, the sixth interview in the series Portrait of Duchenne, our Canadian partners La Fondation La Force talked with Steve Winder at the Action …
July 18, 2017 by abzali123
MNK-1411 is an injection composed of a formulation of tetracosactide, which is a synthetic melanocortin receptor agonist. Melanocortin receptor …
FDA Grants Orphan Designation to Mallinckrodt’s potential drug for DuchenneRead More
Action Duchenne
Wellesley House
Duke of Wellington Avenue Royal Arsenal
London
SE18 6SS
07535 498 506
info@actionduchenne.org